Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

10.5K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
10.5K
Development of the Lymphatic System01:15

Development of the Lymphatic System

2.8K
The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
2.8K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

7.1K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to 'Pink adipose tissue: A paradigm of adipose tissue plasticity' [Ann. Endocrinol. 85 (2004) 248-51].

Annales d'endocrinologie·2026
Same author

Comment on Korakas et al. 780G Hybrid Closed-Loop Pump as Adjunct to Metreleptin in Lipodystrophy-Associated Diabetes: Three Case Observations.

Diabetes care·2026
Same author

Impaired kidney function in People with HIV compared to People without HIV.

AIDS (London, England)·2026
Same author

Maturity Onset Diabetes of the Young (MODY): French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins).

Orphanet journal of rare diseases·2026
Same author

Expansion of NKG2A<sup>+</sup>CD8<sup>+</sup> T cells with regulatory signatures distinguish individuals living with HIV-2 from those with HIV-1.

Med (New York, N.Y.)·2026
Same author

Genomic newborn screening as a paradigm shift in rare disease management, with emphasis on endocrine conditions.

Annales d'endocrinologie·2026

Related Experiment Video

Updated: Apr 15, 2026

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting
07:36

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting

Published on: May 1, 2015

15.1K

Lymphoma in acquired generalized lipodystrophy.

Rebecca J Brown1, Jean L Chan2, Elaine S Jaffe3

  • 1a Diabetes, Endocrinology and Obesity Branch (DEOB), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) , Bethesda , MD , USA.

Leukemia & Lymphoma
|April 14, 2015
PubMed
Summary

Acquired generalized lipodystrophy (AGL) patients face a high risk of developing lymphoma, particularly Peripheral T-cell lymphoma (PTCL). This risk appears linked to autoimmunity, and metreleptin treatment did not directly cause lymphoma in this study.

Keywords:
Acquired generalized lipodystrophyT-cell lymphomaleptinmetreleptinmycosis fungoides

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.8K
A Revised Method for Inducing Secondary Lymphedema in the Hindlimb of Mice
09:50

A Revised Method for Inducing Secondary Lymphedema in the Hindlimb of Mice

Published on: November 2, 2019

8.8K

Related Experiment Videos

Last Updated: Apr 15, 2026

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting
07:36

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting

Published on: May 1, 2015

15.1K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.8K
A Revised Method for Inducing Secondary Lymphedema in the Hindlimb of Mice
09:50

A Revised Method for Inducing Secondary Lymphedema in the Hindlimb of Mice

Published on: November 2, 2019

8.8K

Area of Science:

  • Endocrinology
  • Oncology
  • Immunology

Background:

  • Acquired generalized lipodystrophy (AGL) is a rare autoimmune disorder characterized by adipose tissue loss.
  • Lymphoma, specifically Peripheral T-cell lymphoma (PTCL), has been anecdotally reported in AGL patients.

Observation:

  • This study reports five new cases of lymphoma in AGL patients.
  • Lymphomas were diagnosed both during and without metreleptin treatment.
  • Observed lymphomas included PTCL, anaplastic large cell lymphoma, mycosis fungoides, and Burkitt lymphoma.

Findings:

  • AGL is associated with a significantly increased risk of lymphoma, especially PTCL.
  • Underlying autoimmunity in AGL is a likely contributing factor to lymphomagenesis.
  • Lymphoma development occurred irrespective of metreleptin therapy, suggesting it is not a direct cause.

Implications:

  • The findings suggest metreleptin does not directly cause lymphoma in AGL patients, though a role in progression cannot be excluded.
  • For AGL patients with severe metabolic complications, metreleptin's benefits likely outweigh theoretical lymphoma risks.
  • Further research into the interplay between autoimmunity, AGL, and lymphomagenesis is warranted.